Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: A randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group

European Journal of Cancer

Volumn 42, Issue 17, 2006, Pages 2991-2995

  Punt, C J A ^a   Suciu, S ^b   Gore, M A ^c   Koller, J ^d   Kruit, W H J ^e   Thomas, J ^f   Patel, P ^g   Lienard, D ^h   Eggermont, A M M ^e   Keilholz, U ⁱ  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b EORTC DATA CENTER   (Belgium)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d St Johanns Spital   (Austria)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^h LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

ⁱ FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Chemoimmunotherapy; Cisplatin; Dacarbazine monotherapy; Interferon alpha; Interleukin 2; Metastatic melanoma

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; DACARBAZINE; INTERLEUKIN 2;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CARDIOPULMONARY ARREST; CHRONOTHERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPOTENSION; LETHARGY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MONOTHERAPY; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT INDICATION; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DACARBAZINE; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERON ALFA-2B; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; PATIENT COMPLIANCE; SKIN NEOPLASMS;

EID: 33751031796     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.08.012     Document Type: Article

References (12)

1. Huncharek M., Caubet J.F., and McGarry R. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 11 (2001) 75-81
2. Keilholz U., Punt C.J., Gore M., Kruit W., Patel P., Lienard D., et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organization for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 23 (2005) 6747-6755
3. Keilholz U., Martus P., Punt C.J., Kruit W., Mooser G., Schadendorf D., et al. Prognostic factors for survival and factors associated with long-term remissions in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomized EORTC Melanoma Group trial comparing interferon-alpha and interleukin-2 with or without cisplatin. Eur J Cancer 38 (2002) 1501-1511
4. Keilholz U., Conradt C., Legha S.S., Khayat D., Scheibenbogen C., Thatcher N., et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 16 (1998) 2921-2929
5. Kalbfleisch J.D., and Prentice R.L. The survival analysis of failure time data. second ed. Wiley Series in Probabilities and Statistics (2002), Wiley Inter-Science, New Jersey (USA)
6. Slud E.V., Byar D.P., and Green S.B. A comparison of reflected vs test-based confidence intervals for the median survival time, based on censored data. Biometrics 40 (1984) 587-600
7. Atkins M.B., Lee S., Flaherty L.E., Sosman J.A., Sondak V.K., and Kirkwood J.M. A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with ciplatin, vinblastine, dacarbazine (CVD) IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695), an ECOG coordinated intergroup trial. Proc Am Soc Clin Oncol 22 (2003) 708 [abstract 2847]
8. Bajetta E., Del Vecchio M., Nova P., Fusi A., Daponte A., Sertoli M.R., et al. Multicenter phase III randomized trial of cisplatin, vindesine, and dacarbazine (CVD) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-{alpha}2b in metastatic melanom. Ann Oncol 17 (2006) 571-577
9. Hauschild A., Garbe C., Stolz W., Ellwanger U., Seiter S., Dummer R., et al. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Br J Cancer 84 (2001) 1036-1042
10. Eton O., Legha S.S., Bedikian A.Y., et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 20 (2002) 2045-2052
11. Atzpodien J., Neuber K., Kamanabroe D., Fluck M., Broecker E.B., Neumann C., et al. Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy group (ACIMM). Br J Cancer 86 (2002) 179-184
12. Ridolfi R., Chiarion-Sileni V., Guida M., Romanini A., Labianca R., Freschi A., et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2 and interferon alfa-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 20 (2002) 1600-1607